BG107214A - Пептид, модулиращ тромбопоетиновия рецептор - Google Patents

Пептид, модулиращ тромбопоетиновия рецептор Download PDF

Info

Publication number: BG107214A
Authority: BG; Bulgaria
Prior art keywords: tpo; oligopeptide; oligopeptides; present; cell
Prior art date: 2000-04-25

Application number

BG107214A

Other languages

Bulgarian (bg)

English (en)

Inventor

Tatjana Naranda

Lenard Olsson

Original Assignee

Pliva, Farmaceutska Industrija, Dionicko Drustvo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-25

Filing date

2002-10-23

Publication date

2003-11-28

2002-10-23 Application filed by Pliva, Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva, Farmaceutska Industrija, Dionicko Drustvo

2003-11-28 Publication of BG107214A publication Critical patent/BG107214A/bg

Links

102000005763 Thrombopoietin Receptors Human genes 0.000 title claims 2
108010070774 Thrombopoietin Receptors Proteins 0.000 title claims 2
108090000765 processed proteins & peptides Proteins 0.000 title description 118
108010038807 Oligopeptides Proteins 0.000 claims abstract description 214
102000015636 Oligopeptides Human genes 0.000 claims abstract description 214
102000036693 Thrombopoietin Human genes 0.000 claims abstract description 94
108010041111 Thrombopoietin Proteins 0.000 claims abstract description 94
238000011282 treatment Methods 0.000 claims abstract description 37
150000001413 amino acids Chemical class 0.000 claims abstract description 20
230000004071 biological effect Effects 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
229940075993 receptor modulator Drugs 0.000 claims abstract 2
210000004027 cell Anatomy 0.000 claims description 88
230000000694 effects Effects 0.000 claims description 82
238000000034 method Methods 0.000 claims description 64
239000000243 solution Substances 0.000 claims description 50
206010043554 thrombocytopenia Diseases 0.000 claims description 47
239000000203 mixture Substances 0.000 claims description 46
108090000623 proteins and genes Proteins 0.000 claims description 39
241001465754 Metazoa Species 0.000 claims description 34
239000013598 vector Substances 0.000 claims description 30
238000009739 binding Methods 0.000 claims description 28
230000027455 binding Effects 0.000 claims description 27
238000002512 chemotherapy Methods 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 19
239000002773 nucleotide Substances 0.000 claims description 19
125000003729 nucleotide group Chemical group 0.000 claims description 19
239000000843 powder Substances 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
239000007924 injection Substances 0.000 claims description 14
238000002347 injection Methods 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 13
208000023661 Haematological disease Diseases 0.000 claims description 11
230000014509 gene expression Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
210000001185 bone marrow Anatomy 0.000 claims description 10
238000001514 detection method Methods 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
125000003275 alpha amino acid group Chemical group 0.000 claims description 8
238000003745 diagnosis Methods 0.000 claims description 8
238000002955 isolation Methods 0.000 claims description 8
238000012216 screening Methods 0.000 claims description 8
-1 inhalation solution Substances 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
230000001105 regulatory effect Effects 0.000 claims description 7
238000003018 immunoassay Methods 0.000 claims description 6
239000002502 liposome Substances 0.000 claims description 6
238000001959 radiotherapy Methods 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
241000288906 Primates Species 0.000 claims description 5
230000001580 bacterial effect Effects 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
238000001890 transfection Methods 0.000 claims description 5
238000012546 transfer Methods 0.000 claims description 5
206010020751 Hypersensitivity Diseases 0.000 claims description 4
241000283984 Rodentia Species 0.000 claims description 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
238000000576 coating method Methods 0.000 claims description 4
230000007423 decrease Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
208000014951 hematologic disease Diseases 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
230000007910 cell fusion Effects 0.000 claims description 3
239000011248 coating agent Substances 0.000 claims description 3
239000000839 emulsion Substances 0.000 claims description 3
239000001963 growth medium Substances 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 2
238000004520 electroporation Methods 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
230000031146 intracellular signal transduction Effects 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
229940123936 Thrombopoietin agonist Drugs 0.000 claims 1
239000000443 aerosol Substances 0.000 claims 1
239000008298 dragée Substances 0.000 claims 1
210000002308 embryonic cell Anatomy 0.000 claims 1
238000001802 infusion Methods 0.000 claims 1
229940041682 inhalant solution Drugs 0.000 claims 1
239000006210 lotion Substances 0.000 claims 1
239000002674 ointment Substances 0.000 claims 1
239000006072 paste Substances 0.000 claims 1
230000001177 retroviral effect Effects 0.000 claims 1
239000007921 spray Substances 0.000 claims 1
210000001772 blood platelet Anatomy 0.000 description 54
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 50
229960004562 carboplatin Drugs 0.000 description 50
108020003175 receptors Proteins 0.000 description 36
102000005962 receptors Human genes 0.000 description 36
102220632799 Immunoglobulin heavy variable 1-69_R11A_mutation Human genes 0.000 description 25
102000004196 processed proteins & peptides Human genes 0.000 description 24
235000018102 proteins Nutrition 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 23
150000003839 salts Chemical class 0.000 description 23
108091028043 Nucleic acid sequence Proteins 0.000 description 20
210000003593 megakaryocyte Anatomy 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 19
229940024606 amino acid Drugs 0.000 description 18
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
150000001875 compounds Chemical class 0.000 description 18
238000001727 in vivo Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
241000700159 Rattus Species 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
238000000338 in vitro Methods 0.000 description 14
241000282693 Cercopithecidae Species 0.000 description 13
238000004128 high performance liquid chromatography Methods 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
239000000556 agonist Substances 0.000 description 12
230000015556 catabolic process Effects 0.000 description 12
238000006731 degradation reaction Methods 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000004913 activation Effects 0.000 description 9
238000007792 addition Methods 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000000816 peptidomimetic Chemical class 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
150000002148 esters Chemical class 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
230000026731 phosphorylation Effects 0.000 description 8
238000006366 phosphorylation reaction Methods 0.000 description 8
238000011084 recovery Methods 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
239000000523 sample Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
239000000654 additive Substances 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
238000007796 conventional method Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229960001340 histamine Drugs 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
108020004414 DNA Proteins 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
102000001712 STAT5 Transcription Factor Human genes 0.000 description 6
108010029477 STAT5 Transcription Factor Proteins 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000002243 precursor Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
108090000177 Interleukin-11 Proteins 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
239000005556 hormone Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000007928 intraperitoneal injection Substances 0.000 description 5
238000002372 labelling Methods 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
231100000706 no observed effect level Toxicity 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
239000004475 Arginine Substances 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
208000013544 Platelet disease Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000001476 alcoholic effect Effects 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000011888 autopsy Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000011664 signaling Effects 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
231100000607 toxicokinetics Toxicity 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
210000002798 bone marrow cell Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
239000000428 dust Substances 0.000 description 3
230000034311 endomitotic cell cycle Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000011010 flushing procedure Methods 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
238000010532 solid phase synthesis reaction Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
238000001262 western blot Methods 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
150000008574 D-amino acids Chemical class 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010016825 Flushing Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 2
206010021118 Hypotonia Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
208000007379 Muscle Hypotonia Diseases 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
208000020584 Polyploidy Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001746 atrial effect Effects 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
238000009534 blood test Methods 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229960004926 chlorobutanol Drugs 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000003722 extracellular fluid Anatomy 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000035800 maturation Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000003039 myelosuppressive effect Effects 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
241000894007 species Species 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000012414 sterilization procedure Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
231100000057 systemic toxicity Toxicity 0.000 description 2
230000003582 thrombocytopenic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
230000009466 transformation Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
AENZGWONVTXLRC-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1C(=O)C=CC1=O AENZGWONVTXLRC-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010060935 Alloimmunisation Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102220577005 C5a anaphylatoxin chemotactic receptor 1_Y14F_mutation Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
244000124209 Crocus sativus Species 0.000 description 1
235000015655 Crocus sativus Nutrition 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010075944 Erythropoietin Receptors Proteins 0.000 description 1
102100036509 Erythropoietin receptor Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101000964729 Homo sapiens Zinc finger protein 70 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000042838 JAK family Human genes 0.000 description 1
108091082332 JAK family Proteins 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
206010027906 Monocytosis Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030124 Oedema peripheral Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
239000012722 SDS sample buffer Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229940127323 Thrombopoietin Receptor Agonists Drugs 0.000 description 1
102100034196 Thrombopoietin receptor Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
102100040709 Zinc finger protein 70 Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000002288 cocrystallisation Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000006126 farnesylation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000003862 health status Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000011368 intensive chemotherapy Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000003068 pathway analysis Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000006919 peptide aggregation Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
210000001850 polyploid cell Anatomy 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MVCPDOUDYOUTKS-UHFFFAOYSA-N propanedithioic acid Chemical compound CCC(S)=S MVCPDOUDYOUTKS-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229940095574 propionic acid Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108010000947 protamine zinc Proteins 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000013974 saffron Nutrition 0.000 description 1
239000004248 saffron Substances 0.000 description 1
238000007665 sagging Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
229940001474 sodium thiosulfate Drugs 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
230000001361 thrombopoietic effect Effects 0.000 description 1
229940126460 thrombopoietin receptor agonist Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

BG107214A 2000-04-25 2002-10-23 Пептид, модулиращ тромбопоетиновия рецептор BG107214A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00108075A EP1149906A1 (en)	2000-04-25	2000-04-25	Thrombopoietin receptor modulating peptide
PCT/EP2001/004553 WO2001080873A2 (en)	2000-04-25	2001-04-23	Thrombopoietin receptor modulating peptide

Publications (1)

Publication Number	Publication Date
BG107214A true BG107214A (bg)	2003-11-28

Family

ID=8168467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107214A BG107214A (bg)	2000-04-25	2002-10-23	Пептид, модулиращ тромбопоетиновия рецептор

Country Status (24)

Country	Link
US (1)	US20030181659A1 (pl)
EP (2)	EP1149906A1 (pl)
JP (1)	JP2003530867A (pl)
KR (1)	KR20030009450A (pl)
CN (1)	CN1426467A (pl)
AR (1)	AR030278A1 (pl)
AU (2)	AU6736601A (pl)
BG (1)	BG107214A (pl)
BR (1)	BR0110383A (pl)
CA (1)	CA2407167A1 (pl)
CZ (1)	CZ20023517A3 (pl)
EA (1)	EA006423B1 (pl)
EE (1)	EE200200610A (pl)
GE (1)	GEP20063763B (pl)
HU (1)	HUP0300559A3 (pl)
IL (1)	IL152204A0 (pl)
IS (1)	IS6582A (pl)
MX (1)	MXPA02010458A (pl)
NO (1)	NO20025114L (pl)
PL (1)	PL358304A1 (pl)
SK (1)	SK15262002A3 (pl)
WO (1)	WO2001080873A2 (pl)
YU (1)	YU79202A (pl)
ZA (1)	ZA200208662B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030124596A1 (en) *	2001-11-07	2003-07-03	Millennium Pharmaceuticals, Inc.	Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
US7923431B2 (en) *	2001-12-21	2011-04-12	Ferrosan Medical Devices A/S	Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
DK1542714T3 (da) *	2002-09-18	2014-05-26	Janssen Pharmaceuticals Inc	Fremgangsmåder til forøgelse af produktion af blodplader og hæmatopoietiske stamceller
CA2509914A1 (en)	2002-12-11	2004-06-24	Ferrosan A/S	Gelatine-based materials as swabs
JP2007530440A (ja) *	2003-05-12	2007-11-01	アフィーマックス・インコーポレイテッド	新規ポリ（エチレングリコール）修飾化合物およびその用途
CN1849141A (zh) *	2003-05-12	2006-10-18	阿费麦克斯公司	用于聚(乙二醇)修饰的肽的间隔臂部分
JP2005187435A (ja) *	2003-12-26	2005-07-14	Otsuka Chemical Co Ltd	血小板産生促進組成物
AR054637A1 (es)	2004-01-30	2007-07-11	Ferrosan As	Aerosoles y composiciones hemostaticas
CN101001649B (zh)	2004-07-09	2011-08-31	弗罗桑医疗设备公司	包括透明质酸的止血组合物及其制备方法
ES2373989T3 (es) *	2006-01-31	2012-02-10	Mitsubishi Chemical Medience Corporation	Procedimiento para la determinación del estado de un síndrome de coagulación intravascular diseminada.
CN102014973A (zh)	2008-02-29	2011-04-13	弗罗桑医疗设备公司	用于促进止血和/或伤口愈合的装置
EP2708597B1 (en) *	2011-05-13	2017-11-15	The University of Tokyo	Polynucleated megakaryocytic cell and method for manufacturing platelets
WO2013131520A2 (en)	2012-03-06	2013-09-12	Ferrosan Medical Devices A/S	Pressurized container containing haemostatic paste
RU2636240C2 (ru)	2012-06-12	2017-11-21	Ферросан Медикал Дивайсиз А/С	Сухая гемостатическая композиция
EP3010419B1 (en)	2013-06-21	2020-05-20	Ferrosan Medical Devices A/S	Vacuum expanded dry composition and syringe for retaining same
JP6489485B2 (ja)	2013-12-11	2019-03-27	フェロサンメディカルデバイシーズエイ／エス	押し出し増強因子を含んでいる乾燥組成物
CA2960309A1 (en)	2014-10-13	2016-04-21	Ferrosan Medical Devices A/S	Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru)	2014-12-24	2019-11-12	Ферросан Медикал Дивайсиз А/С	Шприц для удерживания и смешивания первого и второго веществ
AU2016290433B2 (en)	2015-07-03	2018-05-24	Ferrosan Medical Devices A/S	Syringe for mixing two components and for retaining a vacuum in a storage condition
ES2968412T3 (es)	2018-05-09	2024-05-09	Ferrosan Medical Devices As	Método para preparar una composición hemostática
WO2026005476A1 (ko) *	2024-06-26	2026-01-02	주식회사 넥스세라	혈소판 감소증 치료를 위한 재조합 단백질 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5498599A (en) *	1994-01-21	1996-03-12	Amgen Inc.	Methods for stimulating platelet production
AU6046696A (en) *	1995-06-07	1996-12-30	Glaxo Group Limited	Peptides and compounds that bind to a receptor
US6342220B1 (en) *	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
WO1999042127A2 (en) *	1998-02-24	1999-08-26	Receptron, Inc.	Receptor derived peptides as modulators of receptor activity

2000
- 2000-04-25 EP EP00108075A patent/EP1149906A1/en not_active Ceased
2001
- 2001-04-23 US US10/258,565 patent/US20030181659A1/en not_active Abandoned
- 2001-04-23 CA CA002407167A patent/CA2407167A1/en not_active Abandoned
- 2001-04-23 WO PCT/EP2001/004553 patent/WO2001080873A2/en not_active Ceased
- 2001-04-23 EA EA200201138A patent/EA006423B1/ru not_active IP Right Cessation
- 2001-04-23 CZ CZ20023517A patent/CZ20023517A3/cs unknown
- 2001-04-23 JP JP2001577972A patent/JP2003530867A/ja active Pending
- 2001-04-23 PL PL01358304A patent/PL358304A1/pl unknown
- 2001-04-23 AU AU6736601A patent/AU6736601A/xx active Pending
- 2001-04-23 EE EEP200200610A patent/EE200200610A/xx unknown
- 2001-04-23 SK SK1526-2002A patent/SK15262002A3/sk unknown
- 2001-04-23 CN CN01808567A patent/CN1426467A/zh active Pending
- 2001-04-23 EP EP01945029A patent/EP1278849A2/en not_active Withdrawn
- 2001-04-23 YU YU79202A patent/YU79202A/sh unknown
- 2001-04-23 IL IL15220401A patent/IL152204A0/xx unknown
- 2001-04-23 GE GE4988A patent/GEP20063763B/en unknown
- 2001-04-23 AU AU2001267366A patent/AU2001267366B9/en not_active Ceased
- 2001-04-23 BR BR0110383-0A patent/BR0110383A/pt not_active IP Right Cessation
- 2001-04-23 KR KR1020027014262A patent/KR20030009450A/ko not_active Ceased
- 2001-04-23 MX MXPA02010458A patent/MXPA02010458A/es unknown
- 2001-04-23 HU HU0300559A patent/HUP0300559A3/hu unknown
- 2001-04-25 AR ARP010101924A patent/AR030278A1/es unknown
2002
- 2002-10-14 IS IS6582A patent/IS6582A/is unknown
- 2002-10-23 BG BG107214A patent/BG107214A/bg unknown
- 2002-10-24 NO NO20025114A patent/NO20025114L/no not_active Application Discontinuation
- 2002-10-25 ZA ZA200208662A patent/ZA200208662B/xx unknown

Also Published As

Publication number	Publication date
AR030278A1 (es)	2003-08-20
AU6736601A (en)	2001-11-07
YU79202A (sh)	2006-01-16
SK15262002A3 (sk)	2003-05-02
MXPA02010458A (es)	2003-06-06
EA006423B1 (ru)	2005-12-29
EP1149906A1 (en)	2001-10-31
CA2407167A1 (en)	2001-11-01
EE200200610A (et)	2004-08-16
ZA200208662B (en)	2003-10-27
WO2001080873A3 (en)	2002-01-31
NO20025114L (no)	2002-12-18
NO20025114D0 (no)	2002-10-24
EP1278849A2 (en)	2003-01-29
PL358304A1 (pl)	2004-08-09
WO2001080873A2 (en)	2001-11-01
IS6582A (is)	2002-10-14
BR0110383A (pt)	2003-01-21
KR20030009450A (ko)	2003-01-29
AU2001267366B9 (en)	2005-07-14
US20030181659A1 (en)	2003-09-25
EA200201138A1 (ru)	2003-06-26
CZ20023517A3 (cs)	2003-10-15
HUP0300559A3 (en)	2005-09-28
JP2003530867A (ja)	2003-10-21
CN1426467A (zh)	2003-06-25
GEP20063763B (en)	2006-03-10
HUP0300559A2 (hu)	2003-06-28
IL152204A0 (en)	2003-05-29
AU2001267366B2 (en)	2005-06-30

Publication	Publication Date	Title
AU2001267366B2 (en)	2005-06-30	Thrombopoietin receptor modulating peptide
AU2001267366A1 (en)	2002-01-24	Thrombopoietin receptor modulating peptide
WO2010070047A1 (en)	2010-06-24	Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CA2436281A1 (en)	2002-08-08	Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
UA129672C2 (uk)	2025-07-02	Антитіло до trem-1 та його застосування
KR101687060B1 (ko)	2016-12-15	모에신 조절제 및 그의 용도
JP2018522547A (ja)	2018-08-16	Ｉｌ−３７バリアント
TW201609793A (zh)	2016-03-16	去整合蛋白變異體及其醫藥用途
JP7019600B2 (ja)	2022-02-15	加齢黄斑変性症治療用ペプチド
EP1185283B1 (en)	2005-09-07	Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
KR102017973B1 (ko)	2019-09-03	항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
CN115073607A (zh)	2022-09-20	Tnfr2与baff受体的融合蛋白
US7517667B2 (en)	2009-04-14	Methods for promoting, inhibiting and detecting toxin entry into cells
US9617325B2 (en)	2017-04-11	Treatment of IgE-mediated disease
CN112423779B (zh)	2025-04-11	用于治疗色素性视网膜炎的肽
WO2023108666A1 (zh)	2023-06-22	一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
CA3083950A1 (en)	2019-06-06	Trpv6 inhibitors and combination therapies for treating cancers
HK1042727A1 (en)	2002-08-23	Platelet protein receptor modulating peptide
US20090054330A1 (en)	2009-02-26	Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection
AU2016375187C1 (en)	2022-11-24	Soluble glycoprotein V for treating thrombotic diseases
ES2371335T3 (es)	2011-12-30	Identificación y modificación de epítopos inmunodominantes en polipéptidos.